TFAP2A-regulated CRNDE enhances colon cancer progression and chemoresistance via RIPK3 interaction

Xin Gao, Yanming Huang, Tai Wei, Jianxin Xue, Filippov Iurii, Laishou Yang, Liying Wang, Hao Li, Gary Mo, Yuze Huang, Haonan Xie, Hang Wang, Shenghan Lou, Peng HanFunctional 2025 · DOI

Abstract

Colon cancer (CC) is a common malignancy with rising incidence worldwide. Despite advances in treatment strategies, many patients still face a poor prognosis due to the development of drug resistance. Long non-coding RNAs (lncRNAs) have emerged as important regulators of various biological processes and have been implicated in cancer progression. Among them, colorectal neoplasia differentially expressed (CRNDE) has drawn attention for its potential roles in different cancers. However, its specific functions in CC remain unclear. In this study, we identified CRNDE as highly expressed in CC, contributing to tumor progression and drug resistance. Mechanically, CRNDE is regulated by the transcription factor TFAP2A. Additionally, CRNDE inhibits pyroptosis, a form of programmed cell death, by promoting the ubiquitin-mediated degradation of RIPK3, thereby reducing the sensitivity of CC cells to 5-fluorouracil (5-FU). Our findings suggest that the TFAP2A/CRNDE/RIPK3 axis plays critical roles in colon cancer progression and chemoresistance, highlighting potential therapeutic targets for improving treatment outcomes.

Introduction

Colon cancer (CC) remains a leading cause of cancer-related mortality globally. While the standard-of-care chemotherapy, 5-fluorouracil (5-FU), has significantly improved survival rates, the emergence of chemoresistance remains a formidable barrier to successful treatment. Recent research has shifted focus toward the non-coding genome, specifically long non-coding RNAs (lncRNAs), which were once considered genomic "noise" but are now recognized as pivotal regulators of oncogenic signaling.

One such lncRNA, colorectal neoplasia differentially expressed (CRNDE), has been identified as a key player in various malignancies. However, the precise molecular mechanisms by which CRNDE facilitates tumor progression and drug evasion in colon cancer have remained largely unmapped. This study elucidates a novel regulatory pathway involving the transcription factor TFAP2A and the protein RIPK3, providing a new perspective on how tumor cells bypass programmed cell death.

Bioinformatics Discovery of CRNDE

To identify critical lncRNAs in colon cancer, the research team performed an extensive multi-omics analysis. By integrating transcriptomic data from The Cancer Genome Atlas (TCGA-COAD) and five independent Gene Expression Omnibus (GEO) datasets (GSE84983, GSE110715, GSE117830, GSE146009, and GSE180440), the researchers sought genes consistently upregulated across diverse patient cohorts.

Figure 5: Identification of CRNDE as a consistently upregulated lncRNA across multiple colon cancer datasets.

As shown in the Venn diagram analysis, CRNDE emerged as a top candidate, showing significant differential expression in all analyzed datasets. This robust upregulation suggested a fundamental role for CRNDE in colon adenocarcinoma biology.

The TFAP2A/CRNDE/RIPK3 Regulatory Axis

The study further investigated the upstream and downstream components of CRNDE signaling. Using JASPAR and UCSC database predictions combined with ChIP and luciferase reporter assays, the team confirmed that the transcription factor TFAP2A binds directly to the CRNDE promoter, driving its overexpression in CC cells.

Downstream, the mechanism deviates from the common "microRNA sponge" model. Instead, CRNDE was found to physically interact with the RIPK3 protein in the cytoplasm. RIPK3 is a central mediator of pyroptosis—a highly inflammatory form of programmed cell death. CRNDE acts as a molecular scaffold that promotes the K63-linked ubiquitination of RIPK3, tagging it for proteasomal degradation. By depleting RIPK3 levels, CRNDE effectively shields tumor cells from the pyroptotic death typically induced by 5-FU chemotherapy.

Experimental Validation and Chemoresistance

The functional impact of the CRNDE/RIPK3 interaction was validated through a series of in vitro and in vivo experiments. Using RKO and LoVo cell lines, the researchers demonstrated that silencing CRNDE significantly reduced cell proliferation, migration, and invasion. More importantly, CRNDE knockdown lowered the IC50 of 5-FU, making resistant cells sensitive to treatment once again.

Figure 4: Differential expression of CRNDE in colon cancer cell lines and validation of experimental models.

Volcano plots and expression assays confirmed that CRNDE is significantly elevated in malignant cell lines compared to normal NCM460 cells. Furthermore, rescue experiments proved that the chemoresistance granted by CRNDE could be reversed by artificially restoring RIPK3 levels, confirming that RIPK3 degradation is the primary bottleneck for this resistance mechanism.

Conclusion and Future Directions

This research identifies the TFAP2A/CRNDE/RIPK3 axis as a critical driver of colon cancer progression and 5-FU resistance. By hijacking the cell's protein degradation machinery to eliminate RIPK3, CRNDE prevents the induction of pyroptosis, allowing tumors to survive chemical insult.

While these findings offer a promising therapeutic target, the authors note that current models (cell lines and subcutaneous xenografts) do not fully capture the complexity of the human tumor microenvironment. Future work should focus on patient-derived organoids (PDOs) and the development of clinical biomarkers or nanocarrier-based therapies to target CRNDE in patients with chemoresistant colon cancer.

Summary updated

Abstract

Colon cancer (CC) is a common malignancy with rising incidence worldwide. Despite advances in treatment strategies, many patients still face a poor prognosis due to the development of drug resistance. Long non-coding RNAs (lncRNAs) have emerged as important regulators of various biological processes and have been implicated in cancer progression. Among them, colorectal neoplasia differentially expressed (CRNDE) has drawn attention for its potential roles in different cancers. However, its specific functions in CC remain unclear. In this study, we identified CRNDE as highly expressed in CC, contributing to tumor progression and drug resistance. Mechanically, CRNDE is regulated by the transcription factor TFAP2A. Additionally, CRNDE inhibits pyroptosis, a form of programmed cell death, by promoting the ubiquitin-mediated degradation of RIPK3, thereby reducing the sensitivity of CC cells to 5-fluorouracil (5-FU). Our findings suggest that the TFAP2A/CRNDE/RIPK3 axis plays critical roles in colon cancer progression and chemoresistance, highlighting potential therapeutic targets for improving treatment outcomes.
BibTeX
@inproceedings{gao2025tfap,
  author = {Xin Gao and Yanming Huang and Tai Wei and Jianxin Xue and Filippov Iurii and Laishou Yang and Liying Wang and Hao Li and Gary Mo and Yuze Huang and Haonan Xie and Hang Wang and Shenghan Lou and Peng Han},
  title = {{TFAP2A-regulated CRNDE enhances colon cancer progression and chemoresistance via RIPK3 interaction}},
  booktitle = {Functional},
  year = {2025},
  doi = {10.1007/s10142-025-01545-w},
}
Figure